/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

DiaMedica Therapeutics Inc Share Price Today: Live Updates & Key Insights

DiaMedica Therapeutics Inc share price today is $6.735, up -1.25%. The stock opened at $6.78 against the previous close of $6.82, with an intraday high of $6.905 and low of $6.54.

DiaMedica Therapeutics Inc Share Price Chart

style
pb-0

DiaMedica Therapeutics Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

DiaMedica Therapeutics Inc Share Price Performance

$6.735 -0.0125(-1.25%) DMAC at 27 Jul 2026 02:42 PM Biotechnology
Lowest Today 6.54
Highest Today 6.905
Today’s Open 6.78
Prev. Close 6.82
52 Week High 10.42
52 Week Low 4.01
Day’s Range: Low 6.54 High 6.905
52-Week Range: Low 4.01 High 10.42
1 day return -
1 Week return -3.91
1 month return +3.28
3 month return +6.71
6 month return -20.8
1 year return +33.1
3 year return +102.24
5 year return +102.24
10 year return -

DiaMedica Therapeutics Inc Institutional Holdings

Cooperman Leon G 3.75

BlackRock Inc 3.44

iShares Russell 2000 ETF 1.74

Millennium Management LLC 1.74

PARAGON Assoc & PARAGON Assoc II JV 1.62

Geode Capital Management, LLC 1.45

Vanguard Group Inc 1.34

State Street Corp 1.20

First Manhattan Co. LLC 0.84

Bleichroeder LP 0.71

Vanguard Institutional Extnd Mkt Idx Tr 0.66

iShares Russell 2000 Growth ETF 0.64

Fidelity Small Cap Index 0.63

Northern Trust Corp 0.63

Vanguard Capital Management, LLC 0.62

Advisor Group Holdings, Inc. 0.59

LPL Financial Corp 0.42

Vanguard Russell 2000 ETF 0.39

Russell 2000 Equity Index Fund B 0.38

Russell 2000 Index Non-Lendable Fund 0.38

State St Russell Sm/Mid Cp® Indx SL Cl I 0.38

Vanguard Portfolio Management, LLC 0.38

Vanguard Fiduciary Trust Co 0.35

Fidelity Extended Market Index 0.29

Citadel Advisors Llc 0.27

Kalehua Capital Management LLC 0.23

iShares Micro-Cap ETF 0.23

SEI Investments Co 0.21

Bank of New York Mellon Corp 0.21

State St Russell Sm Cap® Idx SL Cl I 0.20

Morgan Stanley - Brokerage Accounts 0.20

Extended Equity Market Fund B 0.17

Extended Equity Market Fund E 0.17

Blackrock Extended Mkt Fund CF 0.17

NT R2000 Index Fund - NL 0.15

BlackRock Extended Equity Market Fund K 0.14

Schwab Small Cap Index 0.14

NT R2000 Index Fund - DC - NL - 3 0.13

Russell 2500™ Index Fund F 0.13

Jacob Discovery Fd Instl 0.12

DiaMedica Therapeutics Inc Market Status

Strong Buy: 3

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

DiaMedica Therapeutics Inc Fundamentals

Market Cap 367.48 M

PB Ratio 7.9111

PE Ratio 0.0

Enterprise Value 322.56 M

Total Assets 61.37 M

Volume 177071

DiaMedica Therapeutics Inc Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-17971000 -18.0M, FY22:-13676000 -13.7M, FY21:-13592000 -13.6M, FY20:-12292000 -12.3M, FY19:-10649000 -10.6M

Quarterly Revenue Q1/2026:0 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M

Quarterly Profit Q1/2026:-11000 -0.0M, Q3/2025:-18000 -0.0M, Q2/2025:-3000 -0.0M, Q1/2025:-11000 -0.0M, Q3/2024:-6883000 -6.9M

Quarterly Net worth Q1/2026:-10042000 -10.0M, Q3/2025:-8620000 -8.6M, Q2/2025:-7699000 -7.7M, Q1/2025:-7707000 -7.7M, Q3/2024:-6274000 -6.3M

About DiaMedica Therapeutics Inc & investment objective

Company Information DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Organisation Biotechnology

Employees 35

Industry Biotechnology

CEO Mr. Dietrich John Pauls MBA

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow

DiaMedica Therapeutics Inc FAQs

What is the share price of DiaMedica Therapeutics Inc today?

The current share price of DiaMedica Therapeutics Inc is $6.735.

Can I buy DiaMedica Therapeutics Inc shares in India?

Yes, Indian investors can buy DiaMedica Therapeutics Inc shares by opening an international trading and demat account with Motilal Oswal.

How to buy DiaMedica Therapeutics Inc shares in India?

You can easily invest in DiaMedica Therapeutics Inc shares from India by:

Can I buy fractional shares of DiaMedica Therapeutics Inc?

Yes, many platforms allow you to buy fractional shares starting from as low as $1.

What is the market capitalization value of DiaMedica Therapeutics Inc?

DiaMedica Therapeutics Inc has a market cap of $367.48 M.

In which sector does DiaMedica Therapeutics Inc belong?

DiaMedica Therapeutics Inc operates in the Biotechnology sector.

What documents are required to invest in DiaMedica Therapeutics Inc stocks?

To invest, you typically need:

What is the PE and PB ratio of DiaMedica Therapeutics Inc?

The PE ratio of DiaMedica Therapeutics Inc is N/A and the PB ratio is 7.91.